Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
Healthcare
$46.41 -0.27%
-$0.12 today
- Market cap
- $3.42B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
52W Low $14.79High $48.53
Volume 0.99M
Average 1.35M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$70.30M
FY 2025 · Annual
Investing Cash Flow
-$173.84M
FY 2025 · Annual
Financing Cash Flow
$218.87M
FY 2025 · Annual
+64.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.74M) | (37.66M) | (71.58M) | (89.02M) | (103.69M) |
| Depreciation & Amortization | 115K | 215K | 297K | 317K | 263K |
| Deferred Income Tax | (3.81M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.92M | 3.19M | 12.91M | 20.17M | 34.02M |
| Change in Working Capital | 3.57M | 438K | 1.4M | (4.54M) | (1.12M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.73M | 411K | (2.25M) | 810K | 817K |
| Other Working Capital | 1.83M | 27K | 3.65M | (5.35M) | (1.94M) |
| Other Non-Cash Items | 3.81M | 1.74M | (4.3M) | (118K) | 232K |
| Operating Cash Flow | (19.13M) | (32.08M) | (61.27M) | (73.19M) | (70.3M) |
| Capital Expenditures | (191K) | (612K) | (149K) | (44K) | (158K) |
| Acquisitions (Net) | 0 | 35M | 0 | 0 | 0 |
| Purchases of Investments | (47.56M) | (35M) | (268.26M) | (350.74M) | (446.79M) |
| Sales of Investments | 45.94M | 41.88M | 120M | 313.91M | 272.9M |
| Other Investing Activities | 1.62M | (41.88M) | 0 | 873K | 213K |
| Investing Cash Flow | (191K) | (612K) | (148.41M) | (36M) | (173.84M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (1.02M) | (1.23M) | 161.2M | 39.19M | 218.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (566K) | 73.09M | 93.98M | 0 |
| Financing Cash Flow | (1.02M) | (1.8M) | 234.29M | 133.17M | 218.87M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (20.34M) | (34.49M) | 24.61M | 23.98M | (25.28M) |
| Free Cash Flow | (19.33M) | (32.69M) | (61.42M) | (73.24M) | (70.46M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$103.7M
+ D&A$263.0K
+ Stock-Based Comp$34.0M
+ Deferred Tax$0
- Working Capital-$1.1M
+ Other Non-Cash$232.0K
= Operating Cash Flow-$70.3M
- Capex-$158.0K
= Free Cash Flow-$70.5M
Analysis
FY2025 free cash flow is -$70.5M. FCF conversion is 67.9% of net income. Operating cash flow was -$70.3M, with capex of -$158.0K. The largest bridge item is Stock-Based Comp at $34.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 21, 2026 |
Does ELVN generate free cash flow?
Enliven Therapeutics, Inc. (ELVN) generated -$70.46M of free cash flow in fiscal 2025.
How much operating cash flow does ELVN produce?
Operating cash flow was -$70.30M, before capital expenditures of $158,000.00.
Continue the stock analysis
Jump to another research area for this company.